论文部分内容阅读
作者报道用α2a重组干扰素(rIFN-α2a)治疗的15例丙型肝炎患者中有3例(20％)产生了高滴度中和抗体(NA),同时有临床复发。经分析,此3例患者的血清能中和成淋巴细胞干扰素(1y-IFN)中存在的10个αIFN亚型,从而说明了对用rIFN-α2治疗而产生抗体介导的耐药性的患者用含有多种αIFN亚型的人细胞来源的干扰素治疗无效的原因。 作者共研究了55例丙型肝炎患者,15例用rlFN-α2a,15例用1y-IFN治疗12月,对照组22例未治疗。收集治疗前后不同时间血清作中和试验。结果只有用rIFN-α2a治疗的15例中有5例(33.3％)出现rlFN-α2aNA。这5例中有3例在治疗12月末,其
The authors reported that 3 (20%) of 15 patients with hepatitis C treated with α2a recombinant interferon (rIFN-α2a) developed high-titer neutralizing antibodies (NA) with clinical relapse. The sera from these 3 patients were analyzed to neutralize the 10 alpha IFN subtypes present in lymphoblast interferon (1y-IFN), thus demonstrating the ability to produce antibody-mediated resistance to treatment with rIFN-alpha2 The reason why patients treated with interferon derived from human cells containing multiple αIFN subtypes is ineffective. The authors studied 55 patients with hepatitis C, 15 patients with rlFN-α2a, 15 patients treated with 1y-IFN in December, the control group of 22 patients untreated. Collection of serum at different times before and after treatment for neutralization test. Results Only rlFN-α2aNA appeared in 5 of 15 (33.3%) patients treated with rIFN-α2a. Three of these five cases were treated by the end of December